ACR 2026: Dapirolizumab Pegol Associated with Greater Treatment Response Rates Versus Placebo in SLE Using Novel Treatment Response Measure

Biogen and UCB’s lupus drug shows strong Phase 3 efficacy, but remains unapproved and long-dated.

What the company is saying

Biogen Inc. (NASDAQ:BIIB) and UCB are highlighting new Phase 3 data for dapirolizumab pegol (DZP), an investigational biologic for systemic lupus erythematosus (SLE), at the ACR Convergence 2026 meeting. The companies emphasize that DZP plus standard of care (SOC) outperformed placebo plus SOC across multiple efficacy endpoints, including SRI-4 response (60% vs 41%), TRM-SLE-50 (61.2% vs 43.2%), and TRM-SLE-100 (52.5% vs 36.8%) at Week 48. They frame the novel TRM-SLE outcome measure as a patient-centric tool that could reshape future clinical trial endpoints, though they acknowledge it is only validated post-hoc and not yet regulatory-accepted. The announcement features commentary from Professor Eric F. Morand (Monash University), Donatello Crocetta (UCB CMO), and Diana Gallagher (Biogen), each underscoring the scientific and patient relevance of the findings. The companies also stress that DZP met the primary endpoint (BICLA response: 50% vs 35%; p=0.011) and showed favorable trends in sustained low disease activity and remission. Safety is described as generally favorable, with more treatment-emergent adverse events but fewer serious ones in the DZP group, and low discontinuation rates. The overall tone is optimistic, with repeated references to advancing the science and improving outcomes, but the companies are clear that DZP is still investigational and not approved anywhere.

What the data suggests

The disclosed figures show that DZP plus SOC achieved higher efficacy rates than placebo plus SOC in the Phase 3 PHOENYCS GO trial: SRI-4 response was 60% (125/208) versus 41% (44/107), TRM-SLE-50 was 61.2% versus 43.2%, and TRM-SLE-100 was 52.5% versus 36.8% at Week 48. The primary endpoint, BICLA response at Week 48, was met with 50% (103/208) for DZP plus SOC versus 35% (37/107) for placebo plus SOC (p=0.011). Sustained low disease activity (LLDAS) was achieved by 24.0% (50/208) of DZP patients versus 10.3% (11/107) of placebo patients, while sustained LLDAS-5 (requiring low steroid dose) was 19.2% versus 5.6%, and sustained DORIS remission was 11.5% versus 4.7%. All efficacy endpoints favored DZP, with nominal p-values indicating statistical significance. Safety data are only summarized qualitatively, stating more treatment-emergent adverse events but fewer serious ones in the DZP arm, and low discontinuation rates in both groups; no numerical breakdown is provided. The TRM-SLE measure, while promising, was applied post-hoc and requires further validation. UCB’s scale is illustrated by 10,000 employees in 40 countries and €7.7 billion in 2025 revenue, but no Biogen-specific financials or commercial projections for DZP are disclosed.

Analysis

The announcement presents detailed Phase 3 clinical data for dapirolizumab pegol (DZP) in SLE, including multiple efficacy endpoints with specific numerical results, which supports the claim of clinical progress. However, DZP remains investigational and is not yet approved, so all commercial or patient benefit is long-term and contingent on further validation and regulatory approval. The tone is optimistic, with forward-looking statements about the potential of the TRM-SLE measure and the hope for improved outcomes, but these are not yet realised. Safety data are described only qualitatively, lacking numerical detail. No financial or commercialisation timelines are disclosed for Biogen, and the only financial figure is UCB's 2025 revenue, which is not directly relevant to DZP's future. The gap between narrative and evidence is moderate: while the clinical data are robust, the announcement inflates the practical impact by discussing potential future benefits and new outcome measures that require further validation.

Risk flags

• ●Regulatory approval risk is high, as DZP is not approved by any health authority and the novel TRM-SLE outcome measure was only used in a post-hoc analysis, not as a pre-specified or regulatory endpoint. This introduces uncertainty about whether regulators will accept these results for approval.
• ●Commercialization risk is significant, since no timeline for regulatory submission, approval, or market launch is provided, and there are no disclosed commercial partnerships or revenue projections tied to DZP.
• ●Safety risk is not fully quantified, as only qualitative statements about adverse events are provided, with no detailed breakdown of event rates or comparison to placebo, leaving gaps in the risk-benefit assessment.
• ●Validation risk for the TRM-SLE measure remains, as further studies are needed to confirm its utility and regulatory acceptability as a primary endpoint in SLE trials. This could delay or complicate future trial designs and approvals.

Bottom line

Biogen and UCB have released robust Phase 3 efficacy data for dapirolizumab pegol in SLE, with all key endpoints favoring the drug over placebo and several results reaching statistical significance. The new TRM-SLE outcome measure shows promise but is not yet validated or accepted by regulators, and its use was limited to a post-hoc analysis. Safety is described as generally favorable, but the lack of detailed numerical safety data leaves some uncertainty. With no regulatory submission or approval timeline disclosed, and DZP still unapproved, any commercial upside is long-dated and contingent on further validation and regulatory acceptance. Investors should view this as a positive scientific milestone but recognize that material financial impact is not imminent. The most important takeaway is that while clinical efficacy is strong, the path to market remains uncertain and extended.

Announcement summary

(NASDAQ:BIIB) Biogen Inc. and UCB announced further data characterizing the clinical profile of dapirolizumab pegol (DZP), an investigational biologic for systemic lupus erythematosus (SLE), presented at ACR Convergence 2026. The data were presented across five posters at the American College of Rheumatology annual meeting in Orlando, Florida, November 6-11. In a post-hoc analysis of the Phase 3 PHOENYCS GO study using the Treatment Response Measure for Systemic Lupus Erythematosus (TRM-SLE), DZP plus standard of care (SOC) was associated with greater proportions of patients achieving a clinically meaningful response through Week 48 in at least half (TRM-SLE-50) or all (TRM-SLE-100) of their active organ domains, mainly joints and skin, versus placebo plus SOC. The PHOENYCS GO study met its primary endpoint of BICLA response at Week 48, with results also favoring DZP for SRI-4 response (60% [125/208] vs 41% [44/107]), a secondary outcome not controlled for multiplicity. In the TRM-SLE analysis, DZP plus SOC through Week 48 was associated with a greater proportion of patients achieving TRM-SLE-50 (61.2% vs 43.2%) and TRM-SLE-100 (52.5% vs 36.8%) compared with placebo plus SOC. At baseline, patients primarily fulfilled the arthritis (joint) and mucocutaneous (skin) TRM-SLE domains. The authors concluded that TRM-SLE distinguished response rates between the treatment arms and offers a potentially practical way to determine response to therapy in SLE, while noting that further validation is needed. TRM-SLE was applied as a post-hoc analysis rather than as a pre-specified endpoint or as part of any regulatory submission. Post-hoc analyses of PHOENYCS GO also examined sustained attainment of low disease activity and remission with DZP plus SOC. Across the final three study visits (Weeks 40, 44 and 48), greater proportions of patients receiving DZP plus SOC versus placebo plus SOC achieved sustained LLDAS (24.0% [50/208] vs 10.3% [11/107]; nominal p=0.0012), sustained LLDAS-5 (19.2% [40/208] vs 5.6% [6/107]; nominal p=0.0002), and sustained DORIS (11.5% [24/208] vs 4.7% [5/107]; nominal p=0.0253). The Phase 3 PHOENYCS GO study was published in The Lancet in May 2026, reporting statistically significant and clinically meaningful improvement in disease activity with DZP plus SOC versus placebo plus SOC at Week 48, as measured by BICLA response (50% [103/208] vs 35% [37/107]; p=0.011). DZP showed a generally favorable safety profile, with safety findings consistent with previous DZP studies. Treatment-emergent adverse events were more common with DZP plus SOC versus placebo plus SOC, while serious treatment-emergent adverse events were less frequent in the DZP plus SOC arm, and discontinuations due to treatment-emergent adverse events were low in both groups. TRM-SLE is a novel clinical outcome assessment developed by a global taskforce led by Monash University, with regulatory input, and measures response in each patient's active organ domains, drawn from six: arthritis, mucocutaneous, nephropathy, serositis, hemolytic anemia, and thrombocytopenia. Dapirolizumab pegol is a novel investigational humanized Fc-free PEG-conjugated antigen-binding (Fab’) fragment that inhibits CD40L signaling, reducing B-cell activation and autoantibody production, mitigating type 1 interferon secretion, and attenuating T-cell and antigen-presenting cell activation. Dapirolizumab pegol is presently in Phase 3 clinical development for SLE under a collaboration between UCB and Biogen. UCB, founded in Belgium in 1928, has more than 10,000 employees in approximately 40 countries and generated revenue of €7.7 billion in 2025. Biogen was founded in 1978.

Disagree with this article?